Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Drugs.com MedNews
Links shared publicly online about this topic.
- 808total visits
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Drugs.com MedNews
THOUSAND OAKS, Calif., Amgen (Nasdaq AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial invo
View full resource at drugs.com
Tags: Cancer, Cancer Medication, Ovarian Cancer, Drug, Women's Health, Taxol, Amgen
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer: THOU... http://bit.ly/b2PL9F #drug
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Health News - redOrbit
redorbit.com — “THOUSAND OAKS, Calif., Oct. 9 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at redorbit.com
Most Recently Shared on October 9, 2010 at 3:29 pm By:
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer: THOUSAND ... http://bit.ly/bNeRSv
Advertisement
